Axonics 관리

관리 기준 확인 3/4

Axonics CEO는 Ray Cohen, Oct2013 에 임명되었습니다 의 임기는 11.08 년입니다. 총 연간 보상은 $ 7.37M, 10.9% 로 구성됩니다. 10.9% 급여 및 89.1% 보너스(회사 주식 및 옵션 포함). 는 $ 20.62M 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 20.62M. 경영진과 이사회의 평균 재임 기간은 각각 7 년과 5.6 년입니다.

주요 정보

Ray Cohen

최고 경영자

US$7.4m

총 보상

CEO 급여 비율	10.9%
CEO 임기	11.1yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	7yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

Axonics' Market Growth Strengthens Boston Scientific's Future

Nov 05

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

CEO 보상 분석

Ray Cohen 의 보수는 Axonics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$2m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$7m	US$800k	-US$6m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$5m	US$750k	-US$60m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$6m	US$625k	-US$80m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$1m	US$527k	-US$55m
Sep 30 2020	n/a	n/a	-US$66m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$81m
Dec 31 2019	US$6m	US$500k	-US$80m
Sep 30 2019	n/a	n/a	-US$67m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$1m	US$430k	-US$32m
Sep 30 2018	n/a	n/a	-US$28m
Jun 30 2018	n/a	n/a	-US$25m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$605k	US$430k	-US$18m

보상 대 시장: Ray 의 총 보상 ($USD 7.37M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.60M ).

보상과 수익: 회사가 수익성이 없는 동안 Ray 의 보상이 증가했습니다.

CEO

Ray Cohen (65 yo)

11.1yrs

테뉴어

US$7,369,375

보상

Mr. Raymond W. Cohen, also known as Ray, is Independent Director of Kestra Medical Technologies, Inc. from July 2024. Mr. Cohen is Venture Advisor of Andera Partners. He focuses on Life Sciences.He works...

리더십 팀

이름	위치	테뉴어	보상	소유권
Raymond Cohen	CEO & Director	11.1yrs	US$7.37m	0.57% $ 20.6m
Kari Keese	Chief Financial Officer	1.1yrs	US$3.76m	0.079% $ 2.8m
Rinda Sama	Chief Operating Officer	6.3yrs	US$3.04m	0.17% $ 6.0m
John Woock	Executive VP	6.4yrs	US$3.26m	0.15% $ 5.5m
Alfred Ford	Chief Commercial Officer	7yrs	US$2.94m	0.085% $ 3.1m
Guangqiang Jiang	Chief Technology Officer	11.1yrs	데이터 없음	데이터 없음
Neil Bhalodkar	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Aaron Pettit	General Counsel & Chief Compliance Officer	no data	데이터 없음	데이터 없음
Michael Williamson	Senior VP	no data	데이터 없음	데이터 없음
Karen Noblett	Chief Medical Officer	7.1yrs	US$651.40k	0.067% $ 2.4m
Prabodh Mathur	Chief Product Development Officer	10.5yrs	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: AXNX 의 관리팀은 노련하고 경험 (평균 재직 기간 7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Raymond Cohen	CEO & Director	11.1yrs	US$7.37m	0.57% $ 20.6m
Michael Carrel	Independent Chairman	5.8yrs	US$250.00k	0.035% $ 1.3m
Nancy Snyderman	Independent Director	5.6yrs	US$222.50k	0.039% $ 1.4m
David Demski	Independent Director	3.8yrs	US$210.00k	0.019% $ 672.2k
Robert McNamara	Independent Director	6yrs	US$227.50k	0.029% $ 1.0m
Jane Kiernan	Independent Director	5.6yrs	US$225.00k	0.039% $ 1.4m
Esteban Lopez	Independent Director	3.3yrs	US$215.00k	0.013% $ 464.8k

5.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: AXNX 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Axonics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

CEO & Director exercised options to buy US$7.1m worth of stock.

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

Chief Medical Officer notifies of intention to sell stock

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Recent updates

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Forecast breakeven date moved forward to 2024

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023)

Axonics' Market Growth Strengthens Boston Scientific's Future

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle

Executive VP notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Axonics prices stock offering of 1.75M shares

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Independent Director notifies of intention to sell stock

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator